跳至主要内容
临床试验/NCT00895817
NCT00895817已完成不适用

Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis

Walter Reed Army Medical Center1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
42
试验地点
1
主要终点
Number of Participants Who Responded

研究概览

简要总结

The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis (EE). EE is an increasingly recognized disorder that has been associated with dysphagia and food impaction. The presence of anatomical abnormalities in the esophagus such as longitudinal furrows, corrugated rings and a narrow caliber esophagus with friable mucosa are classic endoscopic findings. Diagnosis is established with the histologic finding of large numbers (> 15) of eosinophils per high power field. The underlying pathologic mechanism remains poorly understood but food allergies and aeroallergens have been implicated. It is well known that gastroesophageal reflux disease (GERD) may cause esophageal eosinophilia, but it is unclear whether a complex relationship exists between GERD and EE, as recent data suggests. Furthermore, a large number of patients with clinical presentations and endoscopic findings highly suggestive of EE which is confirmed on histology are responding favorably to proton pump inhibitors.

The aims of the study are to (1) compare the clinical efficacy of aerosolized swallowed Fluticasone to Esomeprazole for the treatment of eosinophilic esophagitis, (2) determine whether proton pump inhibitors are effective in the treatment of eosinophilic esophagitis, (3) determine the number of patients with eosinophilic esophagitis that have coexisting gastroesophageal reflux disease, and (4) correlate change in eosinophil count to improvement in symptoms before and after therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with an established diagnosis of EE defined as > 20 eosinophils/HPF in the setting of dysphagia or food impaction.
  • Males and females age > 18 years of age.
  • Ability to undergo ambulatory pH monitoring.
  • DEERS (Defense Enrollment Eligibility Reporting System) eligible.
  • Willingness to take a one month holiday from a PPI or steroids if they have been prescribed this prior to enrollment.
  • Willingness to participate and have additional biopsies taken during endoscopy and answer a questionnaire.

排除标准

  • Patients < 18 years of age.
  • Inability to give consent.
  • Inability to undergo endoscopy or contraindications to endoscopy. Any medical condition or disorder (including drug allergies), which would preclude the use of conscious sedation or the ability to tolerate upper endoscopy.
  • Contraindications to proton pump inhibitors or steroids.
  • Inability to accurately fill out a short questionnaire.
  • Pregnant females. A urine beta human chorionic gonadotropin (BHCG) prior to endoscopy will be offered to all female patients of child bearing potential (exceptions include post-menopausal, hysterectomy or bilateral tubal ligation). Positive BHCG results will prevent enrollment.
  • Known coagulation abnormalities, thrombocytopenia and patients on coumadin.

研究组 & 干预措施

Swallowed fluticasone

Active Comparator

干预措施: Swallowed fluticasone (Drug)

Esomeprazole

Active Comparator

干预措施: Esomeprazole (Drug)

结局指标

主要结局

Number of Participants Who Responded

时间窗: 8 weeks

Histologic resolution of esophageal eosinophilia. Response is defined as achieving \< 7 eosinophils/high power field in both the proximal and distal esophagus.

次要结局

  • Symptom Score(8 weeks)
  • Endoscopic Change(8 weeks)

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Fouad J. Moawad

Principal Investigator

Walter Reed Army Medical Center

研究点 (1)

Loading locations...

相似试验